psoralidin

Also Known As:

3,9-dihydroxy-2-prenylcoumestan; 3-benzofurancarboxylic acid, 2-(2,4-dihydroxy-5-(3-methyl-2-butenyl)phenyl)-6-hydroxy-, delta-lactone; 6H-benzofuro(3,2-C)(1)benzopyran-6-one, 3,9-bis(acetyloxy)-2-(3-methyl-2-buten-1-yl)-; 6H-benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihydroxy-2-(3-methyl-2-buten-1-yl)-; psoralidin diacetate

Networked: 39 relevant articles (7 outcomes, 12 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrans: 130
    - Benzopyrans: 195
      - Coumarins: 826
        psoralidin: 39
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzopyrans: 195
      - Coumarins: 826
        psoralidin: 39
    - Benzofurans: 26
      - psoralidin: 39

Experts

1.	Damodaran, Chendil: 5 articles (06/2017 - 03/2009)
2.	Chen, Xiuping: 3 articles (07/2022 - 01/2014)
3.	Kumar, Raj: 3 articles (09/2010 - 03/2009)
4.	Srinivasan, Sowmyalakshmi: 3 articles (09/2010 - 03/2009)
5.	Lu, Jin-Jian: 2 articles (07/2022 - 08/2016)
6.	Wu, Xue: 2 articles (06/2022 - 01/2019)
7.	Yang, Yang: 2 articles (06/2022 - 01/2019)
8.	Cui, Jiawei: 2 articles (06/2018 - 04/2017)
9.	Feng, Kun: 2 articles (06/2018 - 04/2017)
10.	Kong, Xijian: 2 articles (06/2018 - 04/2017)

Related Diseases

1.	Neoplasms (Cancer) 09/09/2021 - "The anti-cancer effects of Psoralidin were significantly observed after 24 days of the last treatment, confirmed by smaller tumor volume and also H&E staining. " 09/09/2021 - "Psoralidin as a compound of the Psoralea corylifolia seeds exhibited several anti-cancer potentials in various cancers. " 09/09/2021 - "Psoralidin exerts anti-tumor, anti-angiogenic, and immunostimulatory activities in 4T1 tumor-bearing balb/c mice." 09/01/2019 - "Investigation of the in vivo anticancer potential of Psoralidin revealed that this molecule could suppress the growth of xenografted tumors in vivo. " 09/01/2019 - "Flow cytometry showed that Psoralidin triggered G2/M cell cycle arrest of the HepG2 cancer cells. "
2.	Osteoporosis 01/01/2023 - "Psoralidin (PSO) is one of the main bioactive compounds from the seeds of Psoralea corylifolia L and exhibits remarkable protective effects in diseases, including cancer, osteoporosis, and depression. " 01/01/2019 - "Mechanisms explaining the efficacy of psoralidin in cancer and osteoporosis, a review." 01/01/2019 - "Due to prenylation, psoralidin exhibits stronger estrogenic activity with no obvious adverse effects and shows a close association with management of osteoporosis and some cancers. " 06/01/2018 - "Our findings demonstrate that psoralidin, as a novel anti-osteoporosis candidate, could suppress bone loss in OVX rats and have better osteoprotective effects than coumestrol, which may be related to the presence of the isopentenyl group in psoralidin." 04/15/2017 - "Psoralidin, a prenylated coumestan, as a novel anti-osteoporosis candidate to enhance bone formation of osteoblasts and decrease bone resorption of osteoclasts."
3.	Prostatic Neoplasms (Prostate Cancer) 09/01/2010 - "The goal of this study was to determine whether the natural compound psoralidin alters EGFR-mediated signaling resulting in the inhibition of prostate cancer growth. " 02/01/2010 - "Our results suggest that psoralidin inhibits TNF-mediated survival signaling in AIPC and thus is a potent therapeutic agent for prostate cancer." 01/01/2011 - "Our study demonstrated that neobavaisoflavone and psoralidin sensitized TRAIL-resistant cells and markedly augmented TRAIL-mediated apoptosis and cytotoxicity in prostate cancer cells. " 06/27/2017 - "The ability of Psoralidin (Pso), a non-toxic, orally bioavailable compound to inhibit cadmium-induced autophagy to prevent prostate cancer was investigated. " 01/01/2011 - " examined the cytotoxic and apoptotic effects of neobavaisoflavone and psoralidin in combination with TRAIL on LNCaP prostate cancer cells. "
4.	Bone Resorption 04/15/2017 - "Our findings demonstrated that psoralidin and coumestrol exert their bone-protective effects by enhancing bone formation of osteoblasts and inhibiting bone resorption of osteoclasts. " 04/15/2017 - "Interestingly, psoralidin showed much stronger effects than coumestrol at enhancing osteoblast proliferation/differentiation or inhibiting osteoclast differentiation and bone resorption. " 04/15/2017 - "Psoralidin, a prenylated coumestan, as a novel anti-osteoporosis candidate to enhance bone formation of osteoblasts and decrease bone resorption of osteoclasts." 04/15/2017 - "In addition, both psoralidin and coumestrol inhibited osteoclast formation and osteoclastic bone resorption, as demonstrated by the lower tartrate-resistant acid phosphatase activity and smaller area, with fewer resorption pits formed. " 10/01/2017 - "Consistent with in vitro results, our in vivo and serologic studies showed psoralidin inhibited lipopolysaccharide induced bone resorption by suppressing the inflammatory cytokines: TNF-α and IL-6 expression, as well as the ratio of RNAKL : OPG. "
5.	Cardiotoxicity 01/01/2022 - "Protective effects and mechanisms of psoralidin against adriamycin-induced cardiotoxicity."

Related Drugs and Biologics

1.	Coumarins
2.	Coumestrol
3.	VA 061 (VA061)
4.	Interleukin-4 (Interleukin 4)
5.	Doxorubicin (Adriamycin)
6.	esculetin
7.	Lipopolysaccharides
8.	Therapeutic Uses
9.	Fluorescein (Funduscein)
10.	Annexin A5

Related Therapies and Procedures

1.	Chemoprevention
2.	Oral Administration
3.	Therapeutics
4.	Chinese Traditional Medicine (Traditional Chinese Medicine)